InvestorsHub Logo
Followers 1106
Posts 279775
Boards Moderated 10
Alias Born 03/18/2011

Re: None

Thursday, 01/14/2016 3:41:25 PM

Thursday, January 14, 2016 3:41:25 PM

Post# of 8163

$IMNP ~ Bertilimumab was originally developed by Cambridge Antibody Technology (now part of MedImmune, the biologics division of AstraZeneca). CAT licensed Bertilimumab to iCo Therapeutics, who retains the rights to develop ophthalmic indications (Kerato-conjunctivitis, wet Age-related Macular Degeneration) while Immune Pharmaceuticals took responsibility for product supply and all non-ophthalmic indications in June 2011.

http://www.immunepharma.com/product-portfolio/bertilimumab-draft/

$IMNP Website: http://www.immunepharmaceuticals.com/
$IMNP News: http://finance.yahoo.com/q/h?s=IMNP+Headlines
$IMNP Live Chart: http://stockcharts.com/c-sc/sc?s=IMNP&p=d&b=7&g=0&i=p87425001600

Do your DD! Spend only the money you can afford to lose, while still willing to play at other tables. Commissions are cheaper than losses!

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.